Enliven Therapeutics
ELVNEnliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics using a precision medicine approach.
Earnings
Next report
Date not yet announcedValuation & ratios
Competitors
By market cap
By revenue growth
Profile
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics using a precision medicine approach. The company leverages differentiated chemistry and validated biological targets to design therapies that address unmet needs in oncology and other chronic diseases. Its primary goal is to improve patient survival and quality of life through highly selective inhibitors that minimize off-target effects.
A clinical-stage developer of differentiated small molecule inhibitors aiming for best-in-class status through superior selectivity and safety profiles.
FAQ
- What is Enliven Therapeutics's market cap?
- Enliven Therapeutics (ELVN) has a market capitalization of $4.4B and trades on NASDAQ.
- Who are Enliven Therapeutics's competitors?
- Enliven Therapeutics's key competitors include Bristol Myers Squibb, Pfizer, Citius Oncology, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Enliven Therapeutics partner with?
- Enliven Therapeutics's notable partners include Pharmaron, Hande Sciences, Latitude Pharmaceuticals Inc., and others.
- What subsidiaries does Enliven Therapeutics have?
- Enliven Therapeutics's subsidiaries include Former Enliven.
- Where is Enliven Therapeutics headquartered?
- Enliven Therapeutics is headquartered in United States of America and employs approximately 50 people. It has been publicly traded since 2023.